There are a wide range of cognitive disorders associated with schizophrenia: poor memory, impaired attention, difficulty with problem-solving. And the current class of drugs used to treat the hallucinations and delusions associated with schizophrenia have only a limited success with these cognitive disorders. But scientists at the Institute for Neurodegenerative Disorders report that they have identified a drug that has "a normalizing effect on the spontaneous activity of prefrontal cortex neurons." The therapy reverses chemically induced abnormalities in prefrontal cortical functioning. Researcher Bita Moghaddam says that their work can lead the way to the development of new therapies that are specifically targeted at these cognitive disorders.
- see this release